Visp

This research aims to compare two surgical methods for treating large abdominal wall defects, including ventral and incisional hernias. The trial evaluates whether the minimally-invasive, robotically-assisted ventral hernia repair RVHR offers better outcomes than the traditional open ventral hernia repair OVHR. The study focuses on key results such as length of hospital stay after surgery, complication rates, recurrence, reoperations, and quality of life. Participants will undergo either the RVHR or OVHR procedure. The RVHR involves using robotic assistance to place trocars and perform detailed dissection and mesh placement with absorbable sutures. The OVHR is an open surgery with a median laparotomy, adhesiolysis as needed, and mesh placement with optional fixation methods. Both procedures include closure of the abdominal wall layers and dressings designed to keep the study blinded. After surgery, participants will be followed up through in-person visits or remotely via phone or email at day 7, day 30, 6 months, and then at 1, 3, and 5 years. Evaluations include measuring the length of hospital stay, complications, pain, functional recovery, and quality of life using the SF-12 form. Safety and outcomes are monitored during this period to assess the differences between the two surgical methods.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.